Proteome Sciences PLC Director/PDMR Shareholding (1776A)

TIDMPRM

RNS Number : 1776A

Proteome Sciences PLC

07 September 2018

7 September 2018

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 13 August 2018, it purchased 469,866 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the "Purchase"). Following the purchase, Vulpes has a total direct and indirect interest in 58,729,297 equivalent to 19.89% of Proteome Sciences' total issued share capital.

The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes Investment Management and the Company, he now has an interest in 58,729,297 Ordinary Shares of the Company representing 19.89% of the issued share capital of the Company.

The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

 
 1.   Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name:                                      Martin Diggle 
     -----------------------------------------  -------------------------------- 
      Reason for the notification 
     --------------------------------------------------------------------------- 
 a)   Position/status:                           Non-Executive Director 
     -----------------------------------------  -------------------------------- 
 b)   Initial notification/Amendment:            Initial Notification 
     -----------------------------------------  -------------------------------- 
      Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     --------------------------------------------------------------------------- 
 a)   Name:                                      Proteome Sciences Plc 
     -----------------------------------------  -------------------------------- 
 b)   LEI:                                       213800Q62ICXANKU2986 
     -----------------------------------------  -------------------------------- 
      Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     --------------------------------------------------------------------------- 
 a)   Description of the financial instrument,   Ordinary Shares of 1p nominal 
       type of instrument:                        value 
       Identification code:                       GB0003104196 
     -----------------------------------------  -------------------------------- 
 b)   Nature of the transaction:                 Purchase of Ordinary Shares 
     -----------------------------------------  -------------------------------- 
 c)   Price(s) and volume(s):                      Price(s)   Volume(s) 
                                                    3.60       469,866 
                                                              ---------- 
     -----------------------------------------  -------------------------------- 
 d)   Aggregated information:                    Single transaction as in 
        *    Aggregated volume:                   4 c) above Average   Volume(s) 
                                                    Price 
                                                   3.60      469,866 
        *    Price:                                         ---------- 
     -----------------------------------------  -------------------------------- 
 e)   Date of the transaction:                   06/09/18 
     -----------------------------------------  -------------------------------- 
 f)   Place of the transaction:                  London Stock Exchange, 
                                                  AIM (XLON) 
     -----------------------------------------  -------------------------------- 
 

For further information:

 
 Proteome Sciences plc 
 Dr Jeremy Haigh, Chief Executive        Tel: [phone] 
  Officer 
 Dr Ian Pike, Chief Scientific Officer 
  Richard Dennis, Chief Commercial 
  Officer 
 
 finnCap Limited (Nominated Adviser & Broker) 
 Geoff Nash/Hannah Boros (Corporate      Tel: [phone] 
  Finance) 
  Tim Redfern (Broking) 
 

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) ) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator(TM) ). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHSSUFLWFASEDU

(END) Dow Jones Newswires

September 07, 2018 10:43 ET (14:43 GMT)